Google
KURA — KURA ONCOLOGY INC (Healthcare >> Biotechnology)
KURA FAQ
What is KURA's ROE?
KURA ONCOLOGY INC reports a Return on Equity (ROE) of -273.05%.
What is KURA's dividend yield?
KURA ONCOLOGY INC offers a dividend yield of 0.00%.
What is KURA's Deepscope Quality Score?
Deepscope rates KURA's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KURA?
Deepscope's AI Timing Score for KURA is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KURA belong to?
KURA ONCOLOGY INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 8.81
Price
0.25
(2.92%)
Day Change
|
|
|---|
KURA, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.81 |
| PBV / Sector |
7.04 / 4.71
|
| Earning Per Share | -3.42 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
22.54 M
GREAT
|
| Average 1W Daily Value |
18.05 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-10 09:43:59 |
| Symbol | KURA |
| Name | KURA ONCOLOGY INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 88.77 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 759.91 / 8,889.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4930 Directors Place, San Diego, CA, United States, 92121
Phone: 858 500 8800
Website: https://kuraoncology.com
Employees: 260
Sector: Healthcare >> Biotechnology
Description: Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
